Canaccord Genuity Group Issues Positive Forecast for Natera (NASDAQ:NTRA) Stock Price

Natera (NASDAQ:NTRA) had its target price increased by Canaccord Genuity Group from $150.00 to $165.00 in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other brokerages have also commented on NTRA. Piper Sandler restated an “overweight” rating and set a $150.00 price target on shares of Natera in a research note on Friday, September 13th. The Goldman Sachs Group raised their target price on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Sanford C. Bernstein upped their price target on shares of Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. TD Cowen lifted their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Stephens restated an “overweight” rating and set a $125.00 target price on shares of Natera in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.65.

Natera Trading Down 3.3 %

Shares of NTRA opened at $146.06 on Wednesday. The firm has a market capitalization of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera has a 1-year low of $52.01 and a 1-year high of $167.79. The company has a 50-day moving average of $127.38 and a 200 day moving average of $115.61.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the previous year, the business earned ($0.95) earnings per share. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. On average, research analysts expect that Natera will post -1.96 EPS for the current year.

Insider Transactions at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. The trade was a 2.50 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the completion of the transaction, the director now directly owns 19,386 shares in the company, valued at $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,821 shares of company stock worth $4,776,878. Insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Natera

Institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. raised its position in Natera by 19.2% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 9,047 shares of the medical research company’s stock worth $827,000 after buying an additional 1,457 shares during the last quarter. Swiss National Bank raised its holdings in shares of Natera by 1.5% during the first quarter. Swiss National Bank now owns 225,400 shares of the medical research company’s stock worth $20,615,000 after purchasing an additional 3,300 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Natera by 15.1% during the first quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after purchasing an additional 9,781 shares during the period. Bleakley Financial Group LLC purchased a new stake in Natera in the first quarter valued at $223,000. Finally, Entropy Technologies LP acquired a new stake in Natera during the 1st quarter worth about $788,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.